December 9, 2025—According to a press release from Johnson & Johnson, there is "new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001). Ninety-one percent of patients who were progression-free at six months remained progression-free at three years."

The MajesTEC-3 study "evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI® plus DARZALEX FASPRO® versus DARZALEX FASPRO® and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with RRMM who have received 1-3 prior lines of therapy."

This data was presented at the 2025 American Society of Hematology (ASH) Annual Meeting and published in The New England Journal of Medicine. To learn more about this combination regimen that received breakthrough therapy designation from the FDA, click the button below.